sig12d loder
Nucleic acidexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2011 (NCT01188785)
Timeline
Indications
Studied for
Mechanism of action
- GTPase KRasANTISENSE INHIBITOR
KRAS antisense inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594499 ↗
Also known as
- sig12d loder
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01676259 | Phase 2 | Feb 1, 2017 | Cornell University, Silenseed Ltd, Tel Aviv University |
| NCT01188785 | Phase 1 | Jan 1, 2011 | Hebrew University, Silenseed Ltd, Tel Aviv University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Silenseed Ltd | For profit | 2 | 2 | 2 | 2011 |
| Tel Aviv University | Academic/Hospital | 2 | 0 | 2 | 2011 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Hebrew University | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1